Index

Note: Page numbers of article titles are in **boldface** type.

A

Abetalipoproteinemia
  NASH and, 537
Acquired errors of metabolism
  NASH and, 536–537
Amiodarone
  steatohepatitis due to, 527
Anticonvulsant mood stabilizers
  in NASH patients, 622
Antidepressant(s)
  in NASH patients, 621
Antipsychotic agents
  in NASH patients, 622–623
Antiretroviral therapy
  steatohepatitis due to, 530–531
Apoptosis
  as Hh signaling amplifier, 552–553
  markers of
    in noninvasive diagnosis of NASH, 570
  Autocrine signaling, 551

B

Bacterial overgrowth
  NASH due to, 534–535
Ballooning
  in NASH prognosis, 492
Bariatric surgery
  in NASH management, 636–637
Behavioral therapy
  in NASH management, 634–635
Benzodiazepine sedatives
  in NASH patients, 623
Brachial artery
  flow-mediated vasodilation of
    NAFLD and, 601–602
Buspirone
  in NASH patients, 623
C

Cannabis
steatohepatitis due to, 531–532
Canonical signaling, 550–551
Cardiovascular disease (CVD)
NAFLD and
biologic mechanisms in, 606–608
incidence of, 602–606
mortality associated with, 606
Cardiovascular disease (CVD) markers
subclinical
NAFLD and, 600–602
Cardiovascular system
NAFLD and, 599–613. See also Nonalcoholic fatty liver disease (NAFLD), cardiovascular link to
Carotid artery
ultrasound of, 600–601
Celiac disease
NASH and, 536
Chemotherapy-associated steatohepatitis, 530
Children
NAFLD in
vs. adults, 587–598. See also Nonalcoholic fatty liver disease (NAFLD), in children vs. adults
Cholinesterase inhibitors
in NASH patients, 624
Cirrhosis, 557
Computed tomography (CT)
of coronary artery calcifications
NAFLD and, 601
in fibrosis assessment in NASH, 580
CT. See Computed tomography (CT)
CVD. See Cardiovascular disease (CVD)

D

DEAEH. See 4,4′-Diethylaminoethoxyhexestrol (DEAEH)
Diet
in NASH management, 633–634
Dietary factors
in hepatic steatosis, 515–517
4,4′-Diethylaminoethoxyhexestrol (DEAEH)
steatohepatitis due to, 527–529
Drug-induced steatohepatitis, 526–532
amiodarone, 527
antiretroviral therapy, 530–531
cannabis, 531–532
chemotherapies, 530
glucocorticoids, 530
methotrexate, 529–530
perhexiline maleate and DEAEH, 527–529
prevalence of, 526
tamoxifen, 529

Eating disorders
obesity and, 618–619
Elastography
magnetic resonance
in fibrosis assessment in NASH, 579–580
transient
in fibrosis assessment in NASH, 578–579
Enzyme(s)
liver
as surrogate marker in NAFLD diagnosis, 602–603
Epigenetics
in NAFLD, 482–483
Exercise
in NASH management, 634

Familial hypobetalipoproteinemia
NASH and, 537
Fatty liver disease
gut microbiota and, 518–519
Fibrosis. See Liver fibrosis

Gene(s)
in NAFLD, 480–481
Genetic(s)
in hepatic steatosis, 514–515
in NAFLD, 589–590
Genetic diseases
metabolic diseases and, 536–537
Glucocorticoids
steatohepatitis due to, 530
Glucose homeostasis
in hepatic steatosis
micro-RNA regulation of, 517–518
Growth hormone deficiency
NASH and, 532–533
Gut microbiota
fatty liver disease due to, 518–519

HCC. See Hepatocellular carcinoma (HCC)
HDL. See High-density lipoprotein (HDL)
Hedgehog (Hh) ligands, 551
Hedgehog (Hh) signaling pathway
  amplifiers of
    apoptosis and inflammation, 552–553
  canonical signaling, 550–551
  in HCC
    dysregulation of, 557–558
  in injured liver
    activation of, 552
  noncanonical signaling, 551
  overview of, 550–551
  in repair and regeneration, 553–556
    extracellular matrix, 556
    fibrogenesis and fibrogenic repair, 555
    growth of progenitor population of cells and epithelial-to-mesenchymal transition
      response, 554–555
    OPN and fibrogenesis, 556
    vascular remodeling, 556

Hepatic steatosis
  dietary factors in, 515–517
  genetics in, 514–515
  glucose homeostasis in
    micro-RNA regulation of, 517–518
  gut microbiota and, 518–519
  inflammatory factors in, 507–514
  insulin signaling in
    micro-RNA regulation of, 517–518
    mechanisms of, 505–526
  metabolic factors in, 506–514
  transcriptional factors in, 507–514

Hepatocellular carcinoma (HCC)
  Hh signaling in
    dysregulation of, 557–558
  in NASH
    risk factors for, 549–550

Hh signaling pathway. See Hedgehog (Hh) signaling pathway

High-density lipoprotein (HDL)
  in CVD link to NAFLD, 606–608

Histologic scoring systems
  in prediction of clinically meaningful outcomes in NASH, 488–490

Hypobetalipoproteinemia
  familial
    NASH and, 537

Hypothyroidism
  NASH and, 533–534

Hypoxia
  in NAFLD pathogenesis, 471–476

IBD. See Inflammatory bowel disease (IBD)

Inborn errors of metabolism
  NASH and, 536–537
Inflammation
   as Hh signaling amplifier, 552–553
Inflammatory bowel disease (IBD)
   NASH and, 535–536
Inflammatory factors
   in hepatic stenosis, 507–514
Insulin sensitizers
   in NASH management, 635–636
Insulin signaling
   in hepatic steatosis
      micro-RNA regulation of, 517–518
Intestinal factors
   NASH associated with, 534–536

L
Lifestyle modification
   in NASH management, 632–635
      behavioral therapy, 634–635
      dietary recommendations, 633–634
      evidence from controlled trials, 632
      evidence from observational studies, 632–633
      exercise, 634
      weight loss, 635
Ligand(s)
   Hh, 551
Lipodystrophy(ies)
   NASH and, 537
Lipoprotein
   high-density
      in CVD link to NAFLD, 606–608
Lithium
   in NASH patients, 621–622
Liver biopsy
   in NASH diagnosis and staging, 568
      limitations of, 499–500, 568–569
Liver disease(s). See also specific diseases
   pharmacokinetic effects of, 620–621
Liver enzymes
   as surrogate marker in NAFLD diagnosis, 602–603
Liver “fat remodeling” hypothesis
   PNPLA3 and, 469–470
Liver fibrosis
   in NASH
      imaging assessment of, 578–580
         CT in, 580
         MRE in, 579–580
         MRI in, 580
         transient elastography in, 578–579
      prognostic indicators, 490–491
      risk factors for, 549–550
Liver (continued)
  serum markers of, 572–577
    direct markers, 576
    proprietary predictive panels, 576–577
    simple laboratory tests, 572–573
    with clinical markers, 573–576
  stellate cell and, 557
  2-hit model of, 550
Liver histology
  in NASH
    in predicting clinically meaningful outcomes, 487–504. See also Nonalcoholic steatohepatitis (NASH), clinically meaningful outcomes in, liver histology in prediction of

M
Magnetic resonance elastography (MRE)
  in fibrosis assessment in NASH, 579–580
Magnetic resonance imaging (MRI)
  in fibrosis assessment in NASH, 580
Mallory-Denk bodies (MDBs)
  in NASH prognosis, 491–492
MDBs. See Mallory-Denk bodies (MDBs)
Memantine
  in NASH patients, 624
Mental health
  obesity and
    mechanisms linking, 620
Metabolic diseases
  NASH and, 536–537
Metabolic factors
  in hepatic stenosis, 506–514
Methotrexate
  steatohepatitis due to, 529–530
Micro-RNA regulation
  in hepatic steatosis
    in insulin signaling and glucose homeostasis, 517–518
Microbiota
  gut
    fatty liver disease due to, 518–519
Mood/anxiety disorders
  obesity and, 618
MRE. See Magnetic resonance elastography (MRE)
MRI. See Magnetic resonance imaging (MRI)

N
NAFLD. See Nonalcoholic fatty liver disease (NAFLD)
NASH. See Nonalcoholic steatohepatitis (NASH)
Nonalcoholic fatty liver disease (NAFLD)
  cardiovascular link to, 599–613
    biologic mechanisms in, 606–608
    clinical perspective on, 608–609
HDL in, 606–608
incidence of, 602–606
mortality-related, 606
subclinical CVD
  brachial artery flow-mediated vasodilation in, 601–602
coronary artery calcifications in
    CT of, 601
  marker for, 600–602
  pulse-wave velocity in, 602
  ultrasound of carotid artery in, 600–601
in children vs. adults, 587–598
diagnosis, 591–593
genetics, 589–590
histology, 591–593
management, 593–595
natural history, 590–591
pathophysiology of, 589
quality of life, 590–591
described, 587–589
diagnosis of
  in children vs. adults, 591–593
  liver enzymes as surrogate marker in, 602–603
  ultrasound as surrogate marker in, 603–606
epidemiology of
  genetic, 467–485. See also Nonalcoholic fatty liver disease (NAFLD), genetic epidemiology of
epigenetics in, 482–483
gene(s) in, 480–481
genetic architecture of, 476–480
genetic epidemiology of, 467–485
  beyond DNA sequence variation, 482–483
described, 467–469
  future challenges related to, 480–481
  joining effects of genetic variants from multiple pathways, 470–471
  next-generation sequencing techniques
    potential advance generated by, 481–482
PNPLA3 in, 469–470
  prioritization based on previous reported loci, 471–476
  systems biology approaches, 470–471
genetic susceptibility to, 470–471
histology of
  in children vs. adults, 591–593
mortality due to
  CVD and, 606
natural history of
  in children vs. adults, 590–591
obesity and, 616. See also Obesity
pathogenesis of
  molecular mediators of, 471–476
pathophysiology of
  in children vs. adults, 589
Nonalcoholic (continued)
prevalence of, 505, 599–600
quality of life with
  in children vs. adults, 590–591
sexual dimorphism of
  RS738409 variant and, 470
treatment of
  in children vs. adults, 593–595
psychiatric drugs in, 615–629
  recommendations for clinical decision making, 624–625
Nonalcoholic steatohepatitis (NASH)
background of, 567–568
bacterial overgrowth and, 534–535
celiac disease and, 536
clinically meaningful outcomes in
  liver histology in prediction of, 487–504
    histologic features in prognostication, 490–492, 498–500
    ballooning, 490–491
    fibrosis, 492
    MDBs, 491–492
    histologic scoring systems, 488–490
    limitations of, 499–500
    variability in diagnosing individual pathologic lesions, 499
definition of
  lack of consensus for, 499
described, 488, 525–526, 631–632
diagnosis of
  liver biopsy in, 568
  limitations of, 568–569
  noninvasive, 567–585
    apoptosis markers in, 570
    clinical and laboratory variables in, 570
    routine imaging studies in, 570–571
disease progression in
  fibrosis and stellate cell, 557
  mechanisms of, 549–565. See also specific mechanisms and Hedgehog (Hh)
    signaling pathway
    future directions in, 558–559
  repair gone awry, 557–558
fibrosis in
  imaging assessment of, 578–580. See also Liver fibrosis, in NASH, imaging
  assessment of
  risk factors for, 549–550
  serum markers of, 572–577. See also Liver fibrosis, in NASH, serum markers of
growth hormone deficiency and, 532–533
HCC in
  risk factors for, 549–550
histologic progression of, 488
hypothyroidism and, 533–534
IBD and, 535–536
intestinal factors in, 534–536
lipodystrophies and, 537
metabolic diseases and, 536–537
mortality associated with, 493–498
  all-cause related, 493–496
  cardiovascular-related, 496–497
  liver-related, 497
  posttransplant-related, 498
nutritional factors in, 534
pathways to, 525–548
pharmacokinetic effects of, 620–621
prevalence of, 488, 505
staging of
  liver biopsy in, 568
treatment of, 631–645
  bariatric surgery in, 636–637
  future research agenda in, 637
  lifestyle modification in, 632–635. See also Lifestyle modification, in NASH management
pharmacologic, 635–636
psychiatric drugs in
  anticonvulsant mood stabilizers, 622
  antidepressants, 621
  antipsychotics, 622–623
  benzodiazepine sedatives, 623
  buspirone, 623
  cholinesterase inhibitors, 624
  interactions between hypolipidemic and psychiatric drugs, 624
  lithium, 621–622
  memantine, 624
  nonbenzodiazepine sedatives, 623
  pharmacokinetic effects, 620–624
  psychostimulants, 623
psychological, 615–629
  in twenty-first century, 549–550
Noncanonical signaling, 551
Nuclear receptors
  in NAFLD pathogenesis, 471–476
Nutritional factors
  NASH associated with, 534

O

Obesity
  mental health and
    mechanisms linking, 620
NAFLD and, 616
psychiatric disorders and, 617–620. See also specific disorders
  eating disorders, 618–619
  mood/anxiety disorders, 618
Obesity (continued)
  relationship between, 617–620
  schizophrenia, 619–620
  psychological and psychiatric management of, 615–629
  weight-loss interventions for, 616–617
  weight-loss programs for
    suboptimal weight loss and weight regain in, 617
Occupational steatohepatitis, 532
OPN
  fibrogenesis and, 556
Orlistat
  in NASH management, 636

P
Paracrine signaling, 551
Perhexilene maleate
  steatohepatitis due to, 527–529
PNPLA3 gene
  liver “fat remodeling” hypothesis and, 469–470
  NAFLD and, 469–470
  sex interaction and, 470
Psychiatric disorders
  obesity and, 617–620. See also specific disorders and Obesity, psychiatric disorders
  and
Psychostimulants
  in NASH patients, 623
Pulse-wave velocity
  NAFLD and, 602

Q
Quality of life
  NAFLD effects on
    in children vs. adults, 590–591

R
RS738409 variant
  in sexual dimorphism of NAFLD, 470

S
Sex interaction
  gene by
    PNPLA3 and, 470
Steatohepatitis
  chemotherapy-associated, 530
  drug-induced, 526–532. See also Drug-induced steatohepatitis
  nonalcoholic. See Nonalcoholic steatohepatitis (NASH)
  occupational, 532
Steatosis
   diagnosis of
      noninvasive, 569
      clinical and laboratory variables in, 569
   hepatic
      mechanisms of, 505–526. See also Hepatic steatosis
Stellate cells
   liver fibrosis and, 557

T
Tamoxifen
   steatohepatitis due to, 529
Transcriptional factors
   in hepatic stenosis, 507–514
Transient elastography
   in fibrosis assessment in NASH, 578–579

U
Ultrasound
   of carotid artery, 600–601
   as surrogate marker in NAFLD diagnosis, 603–606

V
Vasodilation
   flow-mediated
      of brachial artery
         NAFLD and, 601–602
Vitamin E
   in NASH management, 636

W
Weber-Christian disease
   NASH and, 537
Weight loss
   interventions for, 616–617
   in NASH management, 635
   suboptimal
      in weight-loss programs, 617
Weight-loss programs
   suboptimal weight loss and weight regain in, 617
Weight regain
   in weight-loss programs, 617
Wilson disease
   NASH and, 536